Neo Ivy Capital Management Decreases Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Neo Ivy Capital Management cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 60.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,956 shares of the medical research company's stock after selling 2,946 shares during the quarter. Neo Ivy Capital Management's holdings in Charles River Laboratories International were worth $361,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Optiver Holding B.V. purchased a new stake in shares of Charles River Laboratories International in the 4th quarter worth approximately $37,000. GeoWealth Management LLC lifted its holdings in Charles River Laboratories International by 311.5% during the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after buying an additional 190 shares during the period. Pilgrim Partners Asia Pte Ltd bought a new stake in Charles River Laboratories International during the 4th quarter valued at $48,000. Tortoise Investment Management LLC boosted its position in Charles River Laboratories International by 77.7% during the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock valued at $49,000 after acquiring an additional 115 shares in the last quarter. Finally, Huntington National Bank increased its holdings in shares of Charles River Laboratories International by 120.6% in the 4th quarter. Huntington National Bank now owns 300 shares of the medical research company's stock valued at $55,000 after acquiring an additional 164 shares during the period. 98.91% of the stock is currently owned by institutional investors.

Insider Activity

In other news, EVP Joseph W. Laplume sold 500 shares of the company's stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the sale, the executive vice president now owns 19,513 shares in the company, valued at $2,837,385.33. This represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.30% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on CRL shares. The Goldman Sachs Group cut Charles River Laboratories International from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $190.00 to $170.00 in a research note on Friday, March 21st. Redburn Atlantic upgraded shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and reduced their target price for the stock from $188.00 to $182.00 in a report on Friday, May 23rd. Evercore ISI upgraded shares of Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 price target on the stock in a report on Thursday, May 8th. Barclays lifted their price objective on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 8th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a research report on Thursday, February 20th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $171.85.

Charles River Laboratories International Stock Performance

CRL stock traded down $2.34 during midday trading on Wednesday, reaching $136.31. The stock had a trading volume of 619,557 shares, compared to its average volume of 991,713. The firm has a fifty day simple moving average of $130.77 and a two-hundred day simple moving average of $162.06. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $254.15. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The stock has a market cap of $6.70 billion, a PE ratio of 908.73, a P/E/G ratio of 4.54 and a beta of 1.50.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.06 by $0.28. The firm had revenue of $984.17 million during the quarter, compared to analysts' expectations of $942.34 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company's revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period last year, the business posted $2.27 earnings per share. As a group, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).